Comparison of Clinical Efficacy of Norfloxacin (NFLX) and Pipemidic Acid (PPA) in the Treatment of Infectious Enteritis by a Double-Blind Method
| Autor: | Takakazu AOKI, Nagayo SHIMIZU, Isao TOMIZAWA, Yoshihiko TAKIZAWA, Yoshio MATSUBARA, Takehisa SEO, Hiroko SAGARA, Keiko TAGAWA, Gohta MASUDA, Masayoshi NEGISHI, Chenden YOUNG, Yatsuka IMAGAWA, Misako MURATA, Tsuyoshi YAMAGUCHI, Masachika TSUJI, Jun-ichiro HOSOYA, Ippei FUJIMORI, Yoshio KOBAYASHI, Jyuji HOSHINO, Fukiko AMANO, Chie NAKAMURA, Akira MURAMOTO, Chihiro IMAI, Ryuki KIN, Mitsuru AKAO, Okisuke TSUNODA, Akio TODO, Katsuhiko FUJIMI, Akihiro HIRASA, Kan HASEGAWA, Tadakazu AISAKA, Masanobu NIIMI, Masao TAKEMOTO, Motoko MIKAMI, Toshiko MATSUO, Makoto SAITO, Rintaro NAKAYA, Nobuichi GOTO, Sankichi HORIUCHI, Noboru OKAMURA, Yoshio INAGAKI, Kayoko OZAWA, Yoshifumi TAKEDA |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry Bacillary dysentery Pipemidic acid General Medicine respiratory system Quinolone medicine.disease Antimicrobial Gastroenterology Enteritis Surgery Infectious enteritis Internal medicine medicine Lomefloxacin business Norfloxacin medicine.drug |
| Zdroj: | Journal of the Japanese Association for Infectious Diseases. 61:830-848 |
| ISSN: | 1884-569X 0387-5911 |
| Popis: | The clinical efficacy, safety and usefulness of lomefloxacin (LFLX, NY-198), a new quinolone antimicrobial agent, were compared with those of pipemidic acid (PPA) in the treatment of infectious enteritis (bacillary dysentery, enteropathogenic Escherichia coli enteritis and Campylobacter enteritis) by a double blind method. Daily dosage of LFLX and PPA was 600 mg and 2000 mg, respectively administered orally divided into 4 doses. The duration of the treatment was 5 days. Of 290 cases studied, 100 cases were excluded and 21 cases were dropped from analysis of effectiveness and usefulness. The effectiveness and usefulness was evaluated in 169 cases (LFLX group: 83, PPA group: 86). There was no significance difference between the two groups in any background characteristics. The results obtained were as follows: 1. In 73 symptomatic patients (LFLX group: 35, PPA group: 38) on the day of the beginning of administration, the clinical effect was 91.4% in the LFLX group and 84.2% in the PPA group with no significant difference between the two groups. 2. In a total of 184 strains (LFLX group: 90, PPA group: 94), the bacteriological effects of LFLX (93.3%) was superior to that of PPA (80.9%) with significant difference (p = 0.0153). 3. In 169 evaluable patients, the global clinical effects of LFLX (92.8%) was superior to that of PPA (79.1%) with a significant difference (P = 0.0144). 4. Side effects were observed in 1 (0.7%) of the 141 patients in the LFLX group and none of the 143 patients in the PPA group. Abnormal laboratory test values were noted in 10 (7.6%) of the 132 patients treated with FLLX and 7 (5.1%) of the 136 patients treated with PPA, but they as no significant difference between the two groups. 5. In 169 evaluable patients, the clinical usefulness of LFLX (91.6%) was superior to that of PPA (76.7%) with a significant difference (P = 0.0111). From these results, LFLX is considered to be a clinically useful medicine in the treatment of infectious enteritis including bacillary dysentery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|